Man Group plc Makes New $7.28 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

Man Group plc purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 156,422 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,275,000.

Other institutional investors have also modified their holdings of the company. Sit Investment Associates Inc. grew its position in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after buying an additional 250 shares during the last quarter. Summit Global Investments lifted its position in Supernus Pharmaceuticals by 6.1% during the first quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 256 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in Supernus Pharmaceuticals by 3.6% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares in the last quarter. SummitTX Capital L.P. boosted its stake in Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after acquiring an additional 303 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Supernus Pharmaceuticals by 2.3% in the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 321 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $43.73 on Friday. The stock’s fifty day moving average price is $46.81 and its 200 day moving average price is $48.66. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The company has a market cap of $2.54 billion, a price-to-earnings ratio of -22.78, a PEG ratio of 0.81 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business’s revenue was up 32.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.40 EPS. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SUPN shares. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.